Exploring the Healing Potential of Mistletoe Therapy in Cancer Care
Mistletoe therapy, long integrated into European oncology practices, is gaining global recognition for its ability to enhance the overall well-being of cancer patients. Manufactured by ABNOBA GmbH, a leading German research-based pharmaceutical company, mistletoe extracts are now accessible in India through ABNOBA India, bringing a powerful complementary approach to supportive cancer care.
Unlike conventional treatments that directly target tumors, mistletoe therapy works by stimulating the body’s own defenses. Its active ingredients, including mistletoe lectins, help activate immune cells and regulate the immune response—crucial during cancer treatment, when immunity is often compromised.
One of mistletoe therapy’s most appreciated benefits is its impact on quality of life. Clinical studies have shown that patients receiving mistletoe extracts often report reduced treatment-related fatigue, nausea, and emotional distress, leading to better energy levels and a more stable mental state. Some research also suggests it may help improve treatment adherence and reduce hospitalization time.
Importantly, mistletoe therapy is administered under medical supervision—typically as subcutaneous injections—ensuring safety and compatibility with existing treatments like chemotherapy or radiation.
With ABNOBA India’s commitment to making high-quality, clinically-tested mistletoe products available to Indian patients, integrative cancer care is becoming more accessible than ever. Mistletoe therapy doesn't replace standard treatment, but it can significantly improve how patients feel and function during their journey—making it a valuable addition to holistic cancer support strategies.
Comments
Post a Comment